Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 known ✓ | P30531 | 2/20 | 0.41 |
| ▸ | GABRA5 known ✓ | P31644 | 2/20 | 0.41 |
| ▸ | GABRB2 known ✓ | P47870 | 2/20 | 0.41 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.41 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.41 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.38 |
| ▸ | ITGB3 known ✓ | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B known ✓ | P08514 | 1/20 | 0.38 |
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.41 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.41 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | F2R | P25116 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2558996 | 0.98 | NCF1 (0.43) | NCF1SLC6A1GABRA5GABRB2SLC6A12 | |
| SCHEMBL1108993 | 0.98 | NCF1 (0.43) | NCF1SLC6A1GABRA5GABRB2SLC6A12 | |
| Acetic Acid SCHEMBL7474512 | 0.94 | NCF1 (0.40) | NCF1SLC6A1GABRA5GABRB2SLC6A12 | |
| Hydrochloric Acid SCHEMBL6709111 | 0.91 | NCF1 (0.46) | NCF1SLC6A1GABRA5GABRB2SLC6A12 | |
| SCHEMBL805205 | 0.89 | NCF1 (0.48) | NCF1SLC6A1GABRA5GABRB2SLC6A12 | |
| Hydrochloric Acid SCHEMBL2007871 | 0.88 | SMN1; SMN2 (0.47) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL2607208 | 0.85 | SMN1; SMN2 (0.45) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL15142809 | 0.85 | SMN1; SMN2 (0.45) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL15142807 | 0.85 | SMN1; SMN2 (0.45) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| Hydrochloric Acid SCHEMBL18979999 | 0.84 | SLC6A12 (0.40) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078085-A1 | IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC (CA) | 2026-03-19 | — | — | US | disclosed |
| US-12503432-B2 | Ionizable lipids for nucleic acid delivery | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC (CA) | 2025-12-23 | — | — | US | disclosed |
| US-20250059157-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2025-02-20 | — | — | US | disclosed |
| US-20240067633-A1 | KETOHEXOKINASE INHIBITOR AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-02-29 | — | — | US | disclosed |
| EP-3986866-B1 | IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY | PREC NANOSYSTEMS ULC (CA) | 2023-12-20 | — | — | EP | disclosed |
| CN-114746401-B | Ionizable lipids for nucleic acid delivery | 精密纳米系统无限责任公司 | 2023-12-08 | — | — | CN | disclosed |
| EP-4269404-A1 | KETOHEXOKINASE INHIBITOR AND USE THEREOF | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2023-11-01 | — | — | EP | disclosed |
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| CN-116635377-A | Ketohexokinase inhibitors and uses thereof | 四川海思科制药有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-11629134-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2023-04-18 | — | — | US | disclosed |
| US-10947213-B1 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| WO-2020252589-A1 | IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY | Precision Nanosystems Inc. (CA) | 2020-12-24 | — | — | WO | disclosed |
| US-10696649-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2020-06-30 | — | — | US | disclosed |
| US-20200095222-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-03-26 | — | — | US | disclosed |
| US-10544122-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2020-01-28 | — | — | US | disclosed |
| US-20190330183-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-10-31 | — | — | US | disclosed |
| US-10399957-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2019-09-03 | — | — | US | disclosed |
| EP-3390389-A1 | POLYCYCLIC TLR7/8 ANTAGONISTS AND USE THEREOF IN THE TREATMENT OF IMMUNE DISORDERS | Merck Patent GmbH (DE) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017106607-A1 | POLYCYCLIC TLR7/8 ANTAGONISTS AND USE THEREOF IN THE TREATMENT OF IMMUNE DISORDERS | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | WO | disclosed |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | SLC6A1 4654/4885GABRA5 2654/4885GABRB2 2006/4885 |
| US-20190330183-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | SLC6A1 4654/4885GABRA5 2654/4885GABRB2 2006/4885 |
| US-11629134-B2 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | SLC6A1 4654/4885GABRA5 2654/4885GABRB2 2006/4885 |
| US-20260078085-A1 | IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY | NSUN2, NSUN3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | SLC6A1 1465/4885GABRA5 4753/4885GABRB2 4102/4885 |
| US-10947213-B1 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | SLC6A1 4654/4885GABRA5 2654/4885GABRB2 2006/4885 |
| US-10544122-B2 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | SLC6A1 4654/4885GABRA5 2654/4885GABRB2 2006/4885 |
| US-20200095222-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | SLC6A1 4654/4885GABRA5 2654/4885GABRB2 2006/4885 |
| US-12503432-B2 | Ionizable lipids for nucleic acid delivery | RNASEH1, NSUN3, SLC67A1 | SLC6A1 1564/4885GABRA5 4736/4885GABRB2 4710/4885 |
| US-20250059157-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | SLC6A1 4654/4885GABRA5 2654/4885GABRB2 2006/4885 |
| US-10399957-B2 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | SLC6A1 4612/4885GABRA5 1860/4885GABRB2 1733/4885 |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | SLC6A1 4612/4885GABRA5 1860/4885GABRB2 1733/4885 |
| US-10696649-B2 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | SLC6A1 4654/4885GABRA5 2654/4885GABRB2 2006/4885 |
| US-20240067633-A1 | KETOHEXOKINASE INHIBITOR AND USE THEREOF | KHK, GCK, HK1 | SLC6A1 921/4885GABRA5 3040/4885GABRB2 3174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.